Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality rate. Because the signaling pathways activated by several tyrosine kinase receptors have been shown to be involved in lung fibrosis, it has been suggested that the inhibition of these receptors may slow the progression of idiopathic pulmonary fibrosis. METHODS: In a 12-month, phase 2 trial, we assessed the efficacy and safety of four different oral doses of the tyrosine kinase inhibitor BIBF 1120 as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Secondary end points included acute exacerbations, quality of life (measured with the St. George's Respiratory Questionnaire [SGRQ]), and total lung capacity. RESULTS: A total of 432 patients underwent randomization to receive one of four doses of BIBF 1120 (50 mg once a day, 50 mg twice a day, 100 mg twice a day, or 150 mg twice a day) or placebo. In the group receiving 150 mg of BIBF 1120 twice a day, FVC declined by 0.06 liters per year, as compared with 0.19 liters per year in the placebo group, a 68.4% reduction in the rate of loss with BIBF 1120 (P = 0.06 with the closed testing procedure for multiplicity correction; P = 0.01 with the hierarchical testing procedure). This dose also resulted in a lower incidence of acute exacerbations, as compared with placebo (2.4 vs. 15.7 per 100 patient-years, P = 0.02) and a small decrease in the SGRQ score (assessed on a scale of 0 to 100, with lower scores indicating better quality of life) as compared with an increase with placebo (-0.66 vs. 5.46, P = 0.007). Gastrointestinal symptoms (which led to more discontinuations in the group receiving 150 mg twice a day than in the placebo group) and increases in levels of liver aminotransferases were more frequent in the group receiving 150 mg of BIBF 1120 twice daily than in the placebo group. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was associated with a trend toward a reduction in the decline in lung function, with fewer acute exacerbations and preserved quality of life. (Funded by Boehringer Ingelheim; ClinicalTrials.gov number, NCT00514683 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Bayesian approach incorporated dynamic borrowing of historical placebo data from several external IPF trials, including the ASCEND, INPULSIS, and TOMORROW studies (Figures E2 and E3).2,3,13”
From Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial (2026) · cites this paper as [13]
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Self-citationClinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationBois, R. M. D., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201007-1179oc · Cited by 465
Self-citation
Cited by
Items 201–300 of 1,000
Bendstrup, E. M., Wuyts, W. A., Alfaro, T. M., Chaudhuri, N., Cornelissen, R., Kreuter, M., Nielsen, K. M., Münster, A. B., Myllärniemi, M., Ravaglia, C., et al. (2018) · Respiration · doi:10.1159/000495046 · Cited by 76
for the EMPIRE registry, Tran, T., Šterclová, M., Moğulkoç, N., Lewandowska, K. B., Müller, V., Hájková, M., Kramer, M. R., Jovanović, D., Tekavec-Trkanjec, J., et al. (2020) · Respiratory Research · doi:10.1186/s12931-019-1271-z · Cited by 78
HRCT of fibrosing lung disease
Jacob, J., & Hansell, D. M. (2015) · Respirology · doi:10.1111/resp.12531 · Cited by 79
Self-citationLong-Term Pulmonary Function in Survivors of Childhood Cancer
Armenian, S. H., Landier, W., Francisco, L., Herrera, C., Mills, G., Siyahian, A., Supab, N., Wilson, K. D., Wolfson, J. A., Horak, D. A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.8318 · Cited by 73
Intestinal fibrosis: ready to be reversed
Latella, G., & Rieder, F. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000363 · Cited by 76
Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis
LANCASTER, L. H. (2018) · Multidisciplinary Respiratory Medicine · doi:10.1186/s40248-018-0158-z · Cited by 78
Torok, N. J., Dranoff, J. A., Schuppan, D., & Friedman, S. L. (2015) · Hepatology · doi:10.1002/hep.27720 · Cited by 68
Vianello, A., Arcaro, G., Battistella, L., Pipitone, E., Vio, S., Concas, A., Paladini, L., Gallan, F., Marchi, M. R., Tona, F., et al. (2014) · Journal of Critical Care · doi:10.1016/j.jcrc.2014.03.019 · Cited by 77
Pulmonary Arterial Hypertension in Connective Tissue Diseases
Mathai, S. C., & Hassoun, P. M. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2012.04.001 · Cited by 73
The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis
Kaarteenaho, R. L. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-43 · Cited by 71
Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis
Carneiro, P. J., Clevelario, A. L., Padilha, G. A., Silva, J. D., Kitoko, J. Z., Olsen, P. C., Capelozzi, V. L., Rocco, P. R. M., & Cruz, F. F. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00159 · Cited by 73
Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis
Kondoh, Y., Cottin, V., & Brown, K. K. (2017) · European Respiratory Review · doi:10.1183/16000617.0050-2017 · Cited by 72
Self-citationYamanaka, T., Harimoto, N., Yokobori, T., Muranushi, R., Hoshino, K., Hagiwara, K., Gantumur, D., Handa, T., Ishii, N., Tsukagoshi, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0744-7 · Cited by 75
Update on therapeutic management of idiopathic pulmonary fibrosis
Spagnolo, P., Τzouvelekis, Α., & Bonella, F. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s69716 · Cited by 78
Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats
Wan, Y.-Y., Tian, G.-Y., Guo, H.-S., Kang, Y.-M., Yao, Z.-H., Li, X.-L., Liu, Q.-H., & Lin, D.-J. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-56 · Cited by 66
Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis
Pitre, T., Mah, J. C., Helmeczi, W., Khalid, M. F., Cui, S., Zhang, M., Husnudinov, R., Su, J. S., Banfield, L. E., Guy, B., et al. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-217976 · Cited by 72
Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations
Jo, H. E., Randhawa, S., Corte, T. J., & Moodley, Y. P. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0366-1 · Cited by 79
Bonella, F., Kreuter, M., Hagmeyer, L., Neurohr, C., Keller, C., Kohlhaeufl, M. J., Müller–Quernheim, J., Milger, K., & Prasse, A. (2016) · Respiration · doi:10.1159/000448288 · Cited by 73
Management of Idiopathic Pulmonary Fibrosis
Pleasants, R., & Tighe, R. M. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019862497 · Cited by 63
German Guideline for Idiopathic Pulmonary Fibrosis – Update on Pharmacological Therapies 2017
Behr, J., Günther, A., Bonella, F., Geissler, K. H., Koschel, D., Kreuter, M., Prasse, A., Schönfeld, N., Sitter, H., Müller–Quernheim, J., et al. (2018) · Pneumologie · doi:10.1055/s-0043-123035 · Cited by 71
Self-citationCaminati, A., Madotto, F., Cesana, G., Conti, S., & Harari, S. A. (2015) · European Respiratory Review · doi:10.1183/16000617.0040-2015 · Cited by 71
The treatment of idiopathic pulmonary fibrosis
Woodcock, H. V., & Maher, T. M. (2014) · F1000Prime Reports · doi:10.12703/p6-16 · Cited by 74
Into the matrix: targeting fibroblasts in pulmonary fibrosis
Sivakumar, P., Ntolios, P., Jenkins, G., & Laurent, G. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328356800f · Cited by 67
Determinants of mortality in systemic sclerosis: a focused review
Poudel, D. R., Jayakumar, D., Danve, A. S., Sehra, S. T., & Derk, C. T. (2017) · Rheumatology International · doi:10.1007/s00296-017-3826-y · Cited by 72
Idiopathic Pulmonary Fibrosis: Pathobiology of Novel Approaches to Treatment
Maher, T. M. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.11.002 · Cited by 69
Ho, H. K., Yeo, A. H. L., Kang, T. S., & Chua, B. T. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.021 · Cited by 67
Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema
Τzouvelekis, Α., Zacharis, G., Oikonomou, A., Mikroulis, D. A., Margaritopoulos, G. A., Koutsopoulos, A. V., Ántoniadis, A., Koulelidis, A., Steiropoulos, P., Boglou, P., et al. (2013) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-13-31 · Cited by 71
Takehara, K., Koga, Y., Hachisu, Y., Utsugi, M., Sawada, Y., Saito, Y., Yoshimi, S., Yatomi, M., Shin, Y., Wakamatsu, I., et al. (2022) · Cells · doi:10.3390/cells11010143 · Cited by 64
Mesenchymal Stem Cell Therapy of Pulmonary Fibrosis: Improvement with Target Combination
Chuang, H.-M., Shih, T. E., Lu, K.-Y., Tsai, S.-F., Harn, H., & Ho, L. (2018) · Cell Transplantation · doi:10.1177/0963689718787501 · Cited by 66
Targeting the PDGF Signaling Pathway in the Treatment of Non-Malignant Diseases
Heldin, C.-H. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9484-2 · Cited by 61
Cottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévot, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.017 · Cited by 67
Acute exacerbation of interstitial lung disease after procedures
Amundson, W. H., Racila, E. V., Allen, T. L., Dincer, E. H., Tomic, R., Bhargava, M., Perlman, D., & Kim, H. J. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.02.012 · Cited by 67
Liu, H., Du, K., Li, D., Du, Y., Xi, J., Xu, Y. D., Shen, Y., Jiang, T., & Webster, T. J. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s181002 · Cited by 65
Behr, J., Kolb, M. R. J., Song, J. W., Luppi, F., Schinzel, B., Stowasser, S., Quaresma, M., & Martínez, F. J. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201903-0488oc · Cited by 64
A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer
Vancheri, C., & du Bois, R. M. (2012) · European Respiratory Journal · doi:10.1183/09031936.00115112 · Cited by 63
Tzouvelekis, A., Karampitsakos, Τ., Kontou, M., GRANITSAS, A. N., Malliou, I., Anagnostopoulos, A., Ntolios, P., Tzilas, V., Bouros, E., Steiropoulos, P., et al. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.01.006 · Cited by 66
Lee, Y. E., Go, G.-Y., Koh, E.-Y., Yoon, H.-N., Seo, M., Hong, S.-M., Jeong, J. H., Kim, J.-C., Cho, D., Kim, T. S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006130 · Cited by 61
Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease
Kuwana, M., & Azuma, A. (2019) · Modern Rheumatology · doi:10.1080/14397595.2019.1696505 · Cited by 62
Challenges for Clinical Drug Development in Pulmonary Fibrosis
White, E. S., Thomas, M. J., Stowasser, S., & Tetzlaff, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.823085 · Cited by 68
CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis
Tsoyi, K., Liang, X., Rossi, G. D., Ryter, S. W., Xiong, K., Chu, S. G., Liu, X., Ith, B., Celada, L. J., Romero, F., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202008-3100oc · Cited by 62
Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches
Obi, O. N., Saketkoo, L. A., Russell, A., & Baughman, R. P. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.991783 · Cited by 70
Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
Wollin, S. L., Bonella, F., & Stowasser, S. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s76648 · Cited by 69
Therapeutic pro-fibrogenic signaling pathways in fibroblasts
Cannito, S., Novo, E., & Parola, M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.017 · Cited by 62
Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials
Costabel, U., Behr, J., Crestani, B., Stansen, W., Schlenker‐Herceg, R., Stowasser, S., & Raghu, G. (2018) · Respiratory Research · doi:10.1186/s12931-018-0866-0 · Cited by 65
Self-citationTargeting Alveolar Repair in Idiopathic Pulmonary Fibrosis
Ptasinski, V., Stegmayr, J., Belvisi, M. G., Wagner, D. E., & Murray, L. A. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0476tr · Cited by 65
Comparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis
Loveman, E., Copley, V. R., Scott, D. A., Colquitt, J. L., Clegg, A. J., & O’Reilly, K. M. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0034-y · Cited by 58
Akcora, B. Ö., Storm, G., Prakash, J., & Bansal, R. (2017) · Scientific Reports · doi:10.1038/srep44545 · Cited by 60
Cottin, V. (2013) · European Respiratory Review · doi:10.1183/09059180.00006812 · Cited by 69
Craig, V. J., Polverino, F., Laucho-Contreras, M. E., Shi, Y., Liu, Y., Osorio, J. C., Tesfaigzi, Y., Pinto-Plata, V., Gochuico, B. R., Rosas, I. O., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097485 · Cited by 61
Acute and subacute idiopathic interstitial pneumonias
Taniguchi, H., & Kondoh, Y. (2016) · Respirology · doi:10.1111/resp.12786 · Cited by 61
Role of Receptor Tyrosine Kinase Signaling in Renal Fibrosis
Liu, F., & Zhuang, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060972 · Cited by 64
Iron laden macrophages in idiopathic pulmonary fibrosis: the telltale of occult alveolar hemorrhage?
Puxeddu, E., Comandini, A., Cavalli, F., Pezzuto, G., D'Ambrosio, C., Senis, L., Paci, M., Curradi, G., Sergiacomi, G. L., & Saltini, C. (2014) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2013.12.002 · Cited by 57
“A phase II study of the tyrosine kinase receptor inhibitor Nintedanib has been recently completed [49].”
BackgroundChange in serum marker of oxidative stress in the progression of idiopathic pulmonary fibrosis
Matsuzawa, Y., Kawashima, T., Kuwabara, R., Hayakawa, S., Irie, T., Yoshida, T., Rikitake, H., Wakabayashi, T., Okada, N., Kawashima, K., et al. (2015) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2015.03.005 · Cited by 58
Targeting platelet-derived growth factor as a therapeutic approach in pulmonary fibrosis
Nishioka, Y., Azuma, M., Kishi, M., & Aono, Y. (2013) · The Journal of Medical Investigation · doi:10.2152/jmi.60.175 · Cited by 58
Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease
Bamias, G., Pizarro, T. T., & Cominelli, F. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab251 · Cited by 60
A New Hope for Idiopathic Pulmonary Fibrosis
Hunninghake, G. M. (2014) · New England Journal of Medicine · doi:10.1056/nejme1403448 · Cited by 57
Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis
Hilberg, O., Simonsen, U., du Bois, R. M., & Bendstrup, E. M. (2012) · The Clinical Respiratory Journal · doi:10.1111/j.1752-699x.2012.00302.x · Cited by 56
Suzuki, Y., Aono, Y., Kono, M., Hasegawa, H., Yokomura, K., Naoi, H., Hozumi, H., Karayama, M., Furuhashi, K., Enomoto, N., et al. (2020) · Respirology · doi:10.1111/resp.13943 · Cited by 58
Idiopathic Pulmonary Fibrosis and Post-COVID-19 Lung Fibrosis: Links and Risks
Patrucco, F., Solidoro, P., Gavelli, F., Apostolo, D., & Bellan, M. (2023) · Microorganisms · doi:10.3390/microorganisms11040895 · Cited by 63
Targeting Fibroblast Growth Factor Receptor Signaling in Hepatocellular Carcinoma
Cheng, A., Shen, Y., & Zhu, A. X. (2011) · Oncology · doi:10.1159/000335472 · Cited by 56
Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges
Spagnolo, P., Tonelli, R., Cocconcelli, E., Stefani, A., & Richeldi, L. (2012) · Multidisciplinary Respiratory Medicine · doi:10.1186/2049-6958-7-42 · Cited by 59
Self-citationJo, H. E., Troy, L. K., Keir, G. J., Chambers, D. C., Holland, A. E., Goh, N. S. L., WILSHER, M. L., de Boer, S., Moodley, Y. P., Grainge, C., et al. (2017) · Respirology · doi:10.1111/resp.13146 · Cited by 61
When to start and when to stop antifibrotic therapies
Torrisi, S. E., Pavone, M., Vancheri, A., & Vancheri, C. (2017) · European Respiratory Review · doi:10.1183/16000617.0053-2017 · Cited by 56
Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
Salisbury, M. L., Conoscenti, C., Culver, D. A., Yow, E. S., Neely, M. L., Bender, S. D., Hartmann, N., Palmer, S. M., & Leonard, T. B. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201912-880oc · Cited by 56
STAT3: A Central Mediator of Pulmonary Fibrosis?
Prêle, C. M., Yao, E., O’Donoghue, R. J. J., Mutsaers, S. E., & Knight, D. A. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201201-007aw · Cited by 53
Shimizu, R., Fujimoto, D., Kato, R., Otoshi, T., Kawamura, T., Tamai, K., Matsumoto, T., Nagata, K., Otsuka, K., Nakagawa, A., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2590-x · Cited by 54
Loveman, E., Copley, V. R., Colquitt, J. L., Scott, D. A., Clegg, A. J., Jones, J., O’Reilly, K. M., Singh, S., Bausewein, C., & Wells, A. (2014) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-15-63 · Cited by 52
Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China
Richeldi, L., Rubin, A. S., Avdeev, S. N., Udwadia, Z. F., & Xu, Z. (2015) · BMC Medicine · doi:10.1186/s12916-015-0495-0 · Cited by 54
Self-citationFibroblasts, an inconspicuous but essential player in colon cancer development and progression
Mukaida, N., & Sasaki, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i23.5301 · Cited by 54
Swigris, J. J., Esser, D., Wilson, H., Conoscenti, C., Schmidt, H., Stansen, W., Leidy, N. K., & Brown, K. K. (2016) · European Respiratory Journal · doi:10.1183/13993003.01788-2016 · Cited by 58
Self-citationCottin, V., Martinez, F. J., Jenkins, R. G., Belperio, J. A., Kitamura, H., Molina-Molina, M., Tschoepe, I., Coeck, C., Lievens, D., & Costabel, U. (2022) · Respiratory Research · doi:10.1186/s12931-022-01974-2 · Cited by 53
Self-citationAcute exacerbation of idiopathic pulmonary fibrosis: a proposal
Johannson, K. A., & Collard, H. R. (2013) · Current Respiratory Care Reports · doi:10.1007/s13665-013-0065-x · Cited by 53
Novel inhalation therapy in pulmonary fibrosis: principles, applications and prospects
Zheng, M., Zhu, W., Gao, F., Zhuo, Y., Mo, Z., Wu, G., & Feng, C. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02407-6 · Cited by 56
Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future
Antoniou, K. M., Margaritopoulos, G. A., & Siafakas, N. M. (2013) · European Respiratory Review · doi:10.1183/09059180.00002113 · Cited by 53
Swigris, J. J., Andrae, D. A., Churney, T., Johnson, N., Scholand, M. B., White, E. S., Matsui, A., Raimundo, K., & Evans, C. J. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202002-0415oc · Cited by 54
Lung biopsy in interstitial lung disease: balancing the risk of surgery and diagnostic uncertainty
Cottin, V. (2016) · European Respiratory Journal · doi:10.1183/13993003.01633-2016 · Cited by 57
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
Cottin, V. (2012) · European Respiratory Review · doi:10.1183/09059180.00001112 · Cited by 52
Maher, T. M., Whyte, M. K. B., Hoyles, R. K., Parfrey, H., Ochiai, Y., Mathieson, N., Turnbull, A., Williamson, N., & Bennett, B. M. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0249-6 · Cited by 55
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Antoniou, K. M., & Wells, A. U. (2013) · Respiration · doi:10.1159/000355485 · Cited by 57
Baldi, B. G., Pereira, C. A. D. C., Rubin, A. S., Santana, A. N. C., Costa, A. N., de Carvalho, C. R. R., Algranti, E., Capitani, E. M. D., Bethlem, E. P., Coletta, E. N. A. M., et al. (2012) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132012000300002 · Cited by 52
Salisbury, M. L., Xia, M., Murray, S., Bartholmai, B. J., Kazerooni, E. A., Meldrum, C. A., Martinez, F. J., & Flaherty, K. R. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.07.016 · Cited by 51
Self-citationEarly clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
Toellner, H., Hughes, G., Beswick, W., Crooks, M. G., Donaldson, C., Forrest, I., Hart, S. P., Leonard, C. T., Major, M., Simpson, A. J., et al. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0172-3 · Cited by 52
Cheng, K., Liu, C., & Rao, G. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200514082425 · Cited by 55
Álvarez-Palomo, B., Sánchez-López, L. I., Moodley, Y. P., Edel, M. J., & Serrano‐Mollar, A. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01726-3 · Cited by 58
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review
Luppi, F., Cerri, S., Taddei, S., Ferrara, G., & Cottin, V. (2015) · Internal and Emergency Medicine · doi:10.1007/s11739-015-1204-x · Cited by 56
Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics
Vlieghere, E. D., Verset, L., Demetter, P., Bracke, M., & Wever, O. D. (2015) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-015-1818-4 · Cited by 56
Meinecke, A., Nagy, N., D’Amico, G., Kirmse, S., Klose, R., Schrödter, K., Zimmermann, A., Helfrich, I., Rundqvist, H., Theegarten, D., et al. (2012) · Blood · doi:10.1182/blood-2011-12-396895 · Cited by 50
Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?
Rangarajan, S., Locy, M. L., Luckhardt, T., & Thannickal, V. J. (2016) · Drugs · doi:10.1007/s40265-015-0523-6 · Cited by 56
Normativa sobre el tratamiento farmacológico de la fibrosis pulmonar idiopática
Xaubet, A., Molina‐Molina, M., Acosta, O., Bollo, E., Castillo, D., Fernández‐Fabrellas, E., Rodríguez-Portal, J. A., Valenzuela, C., & Ancochea, J. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2016.12.011 · Cited by 58
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis
Harari, S. A., Caminati, A., Poletti, V. E., Confalonieri, M., Gasparini, S., Lacedonia, D., Luppi, F., Pesci, A., Sebastiani, A., Spagnolo, P., et al. (2018) · Respiration · doi:10.1159/000487711 · Cited by 53
Kalluri, M., Luppi, F., Vancheri, A., Vancheri, C., Balestro, E., Varone, F., Moğulkoç, N., Cacopardo, G., Bargagli, E., Renzoni, E. A., et al. (2021) · European Respiratory Review · doi:10.1183/16000617.0026-2021 · Cited by 55
Alveolar Type II cell transplantation restores pulmonary surfactant protein levels in lung fibrosis
Guillamat‐Prats, R., Gay-Jordi, G., Xaubet, A., Peinado, V. I., & Serrano‐Mollar, A. (2014) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.03.008 · Cited by 50
Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments
Fleetwood, K., McCool, R., Glanville, J., Edwards, S. C., Gsteiger, S., Daigl, M., & Fisher, M. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.3-b.s5 · Cited by 49
VEGFR1-tyrosine kinase signaling in pulmonary fibrosis
Amano, H., Matsui, Y., Hatanaka, K., Hosono, K., & Ito, Y. (2021) · Inflammation and Regeneration · doi:10.1186/s41232-021-00166-7 · Cited by 49
Targeted therapies for systemic sclerosis
Denton, C. P., & Ong, V. H. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.46 · Cited by 52
Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
Rodríguez-Portal, J. A. (2017) · Drugs in R&D · doi:10.1007/s40268-017-0221-9 · Cited by 54
Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases
Liu, F., Bayliss, G. P., & Zhuang, S. (2019) · Clinical Science · doi:10.1042/cs20190249 · Cited by 51
(2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.1925erratum · Cited by 49
Yu, W.-K., Chen, W., Su, V. Y., Shen, H., Wu, H.-H., Chen, H., & Yang, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158193 · Cited by 54
Anti-fibrotic mechanisms of exogenously-expanded mesenchymal stromal cells for fibrotic diseases
Rockel, J. S., Rabani, R., & Viswanathan, S. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.10.014 · Cited by 51
Metadata
- Authors
- Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., Brun, M., Gupta, A., Juhel, N., Klüglich, M., & du Bois, R. M.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Ruhrlandklinik (DE)
- Asan Medical Center (KR)
- Royal Brompton Hospital (GB)
- Michigan Medicine (US)
- Duke Medical Center (US)
- University of Washington (US)
- Boehringer Ingelheim (France) (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-09-22
- Volume
- 365
- Issue
- 12
- Pages
- 1079-1087
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152974152
- Cited by
- 1,157
- References
- 22
- Citations by year
- 2026: 32 · 2025: 50 · 2024: 79 · 2023: 74 · 2022: 83 · 2021: 86 · 2020: 73 · 2019: 72 · 2018: 91 · 2017: 102 · 2016: 88 · 2015: 100 · 2014: 71 · 2013: 80 · 2012: 61
- FWCI
- 60.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, nintedanib, tyrosine kinase inhibitors, forced vital capacity decline, lung fibrosis progression, acute exacerbation, quality of life, gastrointestinal adverse effects, liver aminotransferases, dose comparison, St George's Respiratory Questionnaire, total lung capacity, drug safety and efficacy
- MeSH terms
- Adult, Aged, Alanine Transaminase, Aspartate Aminotransferases, Enzyme Inhibitors, Female, Humans, Indoles, Liver, Male, Middle Aged, Protein-Tyrosine Kinases, Vital Capacity, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.